New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
11:13 EDTYUM, AEP, VRX, ED, TGT, PWE, JPM, SPLS, ESIOptions with increasing implied volatility
Options with increasing implied volatility: ESI SVXY PWE VRX SPLS TGT AEP JPM ED YUM
News For ESI;PWE;VRX;SPLS;TGT;AEP;JPM;ED;YUM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
November 18, 2014
15:17 EDTSPLSStaples technical comments ahead of earnings
Subscribe for More Information
15:08 EDTTGTTarget technical comments ahead of results
The stock in the past three months has outperformed the broader averages, trading up over 14%. Most of that outperformance has been in recent days leading up to earnings. That move broke the shares out of a very narrow trading range that had persisted for two months. With the shares trading close to the 52-week high at $68.28, strong positive news or an upside surprise could propel the stock through that level and to the lifetime high at $73.50. A failure to break through the $70 area, particularly on a negative surprise, could leave the shares vulnerable to a larger than normal correction. On a long-term basis a failure at $70 would be a third attempt up that failed at resistance. Support levels to watch as potential downside objectives would be at $64.65, $61.46, and $59.57. The low of the range prior to the recent breakout was at $54.66, which is the 52-week low.
14:46 EDTSPLSStaples November volatility elevated into Q3 and outlook
Subscribe for More Information
13:34 EDTVRXActavis rallies after analysts push targets north of $300
Shares of drug maker Actavis (ACT) are climbing after a number of analysts cheered the company's acquisition of Allergan (AGN), and activist investor Bill Ackman said he supported the transaction, according to CNBC. WHAT'S NEW: Piper Jaffray analyst David Amsellem responded to Actavis' acquisition of Allergan by hiking his price target on the name to $338 from $280. The combined company has durable assets, a cost-efficient infrastructure, and the willingness to maintain a strong R&D infrastructure, contended Amsellem. Actavis' price-to-earnings ratio is likely to increase, since it has durable assets, while it his very likely to sustain growth of at least 10%, the analyst added. He kept an Overweight rating on the shares. Also extremely upbeat on Actavis following the deal was UBS analyst Marc Goodman. Actavis provides "the best value in the sector" following the deal, as the transaction should accelerate the company's revenue and profit growth, Goodman believes. That growth, in turn, should propel Actavis' price-to-earnings multiple higher, the analyst predicted. He hiked his price target on Actavis to $333 from $278 and kept a Buy rating on the stock. Meanwhile, Pershing Square's Bill Ackman said that he supported Actavis' takeover of Allergan, CNBC reported this morning. The owner of a large stake in Allergan, Ackman had been trying to get the drug maker to sell itself to Valeant (VRX). The activist investor said today that he would no longer push Allergan to hold a special meeting on December 18, CNBC noted. PRICE ACTION: In mid-afternoon trading, Actavis surged 7.5% to $266.50, while Allergan gained 2% to $214.
12:44 EDTTGTEarnings Preview: Target sees FY14 adjusted EPS view of $3.10-$3.30
Subscribe for More Information
09:01 EDTJPMJPMorgan announces municipal bond agreement with LPL Financial
JPMorgan Chase & Co. (JPM) announced that it has signed an agreement with LPL Financial (LPLA) to provide access to new issue municipal bonds to LPL financial advisors. Under the agreement, LPL will be a preferred retail dealer for J.P. Morgan, further expanding the investment bankís distribution channels for new issue municipal bonds.
08:02 EDTVRXValeant announces FDA, Health Canada approval to market Ideal Implant
Valeant Pharmaceuticals and Ideal Implant Incorporated announced the receipt of approval from the U.S. Food and Drug Administration and Health Canada to market the IDEAL IMPLANT Saline-filled Breast Implant for use in primary breast augmentation or replacement of existing augmentation implants. The FDA approval of the IDEAL IMPLANT was based on an extensive review of various studies and data including a U.S. clinical trial that began in 2009 with 45 plastic surgeons and 502 women, who underwent breast augmentation or replacement of augmentation implants. The clinical trial is on-going and will continue to provide follow-up data through 2020.
07:53 EDTTGTTarget November volatility elevated into Q3 and outlook
Subscribe for More Information
07:48 EDTVRXValeant not likely to raise bid for Allergan, says Canaccord
Subscribe for More Information
06:49 EDTVRXValeant likely to pursue more moderate-sized deals, says Piper Jaffray
Subscribe for More Information
November 17, 2014
14:21 EDTTGTEarnings Preview: Home Depot shares up over 17% since last earnings report
Subscribe for More Information
10:06 EDTJPMSears Canada, JPMorgan Chase announce changes to credit card program
Subscribe for More Information
09:32 EDTVRXValeant says cannot justify paying $219 per share for Allergan
Valeant Pharmaceuticals (VRX) commented on the announcement that Allergan (AGN) and Actavis (ACT) have entered into a definitive agreement under which Actavis will acquire all outstanding shares of Allergan stock: "We have seen the announcement that Allergan and Actavis have made, and while we will review any such agreement in determining our course of action, Valeant cannot justify to its own shareholders paying a price of $219 or more per share for Allergan. Our business is performing extremely well as evidenced by our third quarter results, our expected strong fourth quarter, and our robust outlook for 2015, and I am confident in our continued ability to generate exceptional shareholder value. We will remain focused on delivering strong organic results and evaluating acquisition opportunities as we always have: prudently, in a disciplined manner, and in the best interests of our shareholders."
09:05 EDTPWEPenn West board approves $840M capital budget for 2015
Penn West reports its board has approved a 2015 capital budget of approximately $840M. The company expects to spud approximately 225, or 212 net, wells in 2015, over 90% of which will be drilled in the three core light oil areas. 2015 forecast average production is expected to be between 95,000 and 105,000 boe per day, weighted approximately 69% toward oil and liquids. The company's updated Long-Term Plan targets compound annual growth rates between 2015 and 2019 of approximately 13% for oil in terms of average daily production volumes, and over eight percent in terms of our total boe average daily production volumes, which is expected to drive a funds flow CAGR between 2015 and 2019 of over 20%. These targets are based on what the company believes to be conservative commodity pricing assumptions.
09:01 EDTPWEPenn West to host conference call
Subscribe for More Information
07:42 EDTTGTTarget looks to put massive breach in rear-view one year later, WSJ says
Encouraging signs are appearing for Target as the company looks to put its massive data breach in the rear view mirror about one year later as it reports earnings this Wednesday, said The Wall Street Journal's "The Week Ahead" column. Target shares are near 2014 highs after analysts have recently reported a pickup in foot traffic at its stores, the article noted. Reference Link
06:18 EDTJPMJPMorgan reports October net credit losses 2.26% vs. 2.24% last month
Reports October delinquency rate 1.34% vs. 1.30% last month.
06:05 EDTVRXActavis close to buying Allergan for over $64B, Bloomberg reports
Subscribe for More Information
November 16, 2014
17:42 EDTJPMJPMorgan settles mineral rights suit in Texas, Bloomberg says
JPMorgan settled a lawsuit by Texas mineral-rights owners that accused the bank of negotiating "sweetheart deals" with oil company clients to cheat them out of $681M in compensation, says Bloomberg. Beneficiaries of the South Texas Syndicate Trust alleged that JPMorgan entered into favorable deals for its commercial banking clients on the trustís rights in the Eagle Ford, added Bloomberg. Reference Link
14:02 EDTVRXAllergan, Actavis move closer to deal, WSJ reports
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use